Yahoo
Canadian Sec - Delayed Quote CAD

Optimi Health Corp. (OPTI.CN)

3.6000 -0.0200 (-0.55%)
At close: October 30 at 3:57:06 PM EDT
Chart Range Bar
Loading chart for OPTI.CN
  • Previous Close 3.6200
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 12.1500
  • Volume 0
  • Avg. Volume 4,759
  • Market Cap (intraday) 20.613M
  • Beta (5Y Monthly) 1.61
  • PE Ratio (TTM) --
  • EPS (TTM) -2.1500
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 15.00

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.

www.optimihealth.ca

--

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

OPTI.CN
63.08%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

OPTI.CN
61.29%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

OPTI.CN
29.41%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

OPTI.CN
80.95%
S&P/TSX Composite index (^GSPTSE)
69.32%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 140.2k
Earnings --
Profit Margin 0.00%

Q2

FY26

Q3

FY26

0
50K
100K
0.0%

Analyst Insights

View More

Analyst Price Targets

15.00
15.00 Average
3.6000 Current
15.00 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -16.06%

  • Return on Equity (ttm)

    -54.36%

  • Revenue (ttm)

    175.67k

  • Net Income Avi to Common (ttm)

    -6.9M

  • Diluted EPS (ttm)

    -2.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.07M

  • Total Debt/Equity (mrq)

    29.17%

  • Levered Free Cash Flow (ttm)

    -1.73M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: